380 related articles for article (PubMed ID: 15696783)
21. Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease.
Josephs KA; Parisi JE; Knopman DS; Boeve BF; Petersen RC; Dickson DW
Arch Neurol; 2006 Apr; 63(4):506-12. PubMed ID: 16606762
[TBL] [Abstract][Full Text] [Related]
22. The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease.
Mackenzie IR; Feldman H
Acta Neuropathol; 2003 Feb; 105(2):98-102. PubMed ID: 12536219
[TBL] [Abstract][Full Text] [Related]
23. Motor neuron disease with dementia combined with degeneration of striatonigral and pallidoluysian systems.
Sudo S; Fukutani Y; Matsubara R; Sasaki K; Shiozawa M; Wada Y; Naiki H; Isaki K
Acta Neuropathol; 2002 May; 103(5):521-5. PubMed ID: 11935270
[TBL] [Abstract][Full Text] [Related]
24. Alpha-synuclein in motor neuron disease: an immunohistologic study.
Doherty MJ; Bird TD; Leverenz JB
Acta Neuropathol; 2004 Feb; 107(2):169-75. PubMed ID: 14648076
[TBL] [Abstract][Full Text] [Related]
25. Neurofilament inclusion body disease with early onset frontotemporal dementia and primary lateral sclerosis.
Mackenzie IR; Feldman H
Clin Neuropathol; 2004; 23(4):183-93. PubMed ID: 15328884
[TBL] [Abstract][Full Text] [Related]
26. Expression of the intermediate filament protein synemin in myofibrillar myopathies and other muscle diseases.
Olivé M; Goldfarb L; Dagvadorj A; Sambuughin N; Paulin D; Li Z; Goudeau B; Vicart P; Ferrer I
Acta Neuropathol; 2003 Jul; 106(1):1-7. PubMed ID: 12669240
[TBL] [Abstract][Full Text] [Related]
27. Animal models for motor neuron disease.
Green SL; Tolwani RJ
Lab Anim Sci; 1999 Oct; 49(5):480-7. PubMed ID: 10551448
[TBL] [Abstract][Full Text] [Related]
28. [Inclusion body myositis associated with sacroidosis: a report of 3 cases].
Bouillot S; Coquet M; Ferrer X; Lagueny A; Leroy JP; Vital C
Ann Pathol; 2001 Aug; 21(4):334-6. PubMed ID: 11685131
[TBL] [Abstract][Full Text] [Related]
29. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis.
Lünemann JD; Schmidt J; Schmid D; Barthel K; Wrede A; Dalakas MC; Münz C
Ann Neurol; 2007 May; 61(5):476-83. PubMed ID: 17469125
[TBL] [Abstract][Full Text] [Related]
30. Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle.
Broccolini A; Gidaro T; De Cristofaro R; Morosetti R; Gliubizzi C; Ricci E; Tonali PA; Mirabella M
J Neurochem; 2008 May; 105(3):971-81. PubMed ID: 18182043
[TBL] [Abstract][Full Text] [Related]
31. Messenger RNA degradation may be inhibited in sporadic inclusion body myositis.
Nakano S; Shinde A; Ito H; Ito H; Kusaka H
Neurology; 2005 Aug; 65(3):420-5. PubMed ID: 16087907
[TBL] [Abstract][Full Text] [Related]
32. Unusual association of sporadic olivopontocerebellar atrophy and motor neuron disease.
Testa D; Tiranti V; Girotti F
Neurol Sci; 2002 Dec; 23(5):243-5. PubMed ID: 12522682
[TBL] [Abstract][Full Text] [Related]
33. [Significance of rimmed vacuoles in neuromuscular disorders--a comparative immunohistochemical study of inclusion body myositis and distal myopathy with rimmed vacuole formation].
Murakami N; Takemitsu M; Kurashige T; Nonaka I
Rinsho Shinkeigaku; 1994 Aug; 34(8):782-7. PubMed ID: 7994984
[TBL] [Abstract][Full Text] [Related]
34. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.
Askanas V; Engel WK
Neurology; 2006 Jan; 66(2 Suppl 1):S39-48. PubMed ID: 16432144
[TBL] [Abstract][Full Text] [Related]
35. New insights into the skeletal muscle phenotype of equine motor neuron disease: a quantitative approach.
Palencia P; Quiroz-Rothe E; Rivero JL
Acta Neuropathol; 2005 Mar; 109(3):272-84. PubMed ID: 15616793
[TBL] [Abstract][Full Text] [Related]
36. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
37. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers.
Nogalska A; D'Agostino C; Engel WK; Klein WL; Askanas V
Acta Neuropathol; 2010 Nov; 120(5):661-6. PubMed ID: 20711838
[TBL] [Abstract][Full Text] [Related]
38. Familial amyotrophic lateral sclerosis with posterior column degeneration and basophilic inclusion bodies: a clinical, genetic and pathological study.
Tsuchiya K; Matsunaga T; Aoki M; Haga C; Ooe K; Abe K; Ikeda K; Nakano I
Clin Neuropathol; 2001; 20(2):53-9. PubMed ID: 11327297
[TBL] [Abstract][Full Text] [Related]
39. Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects.
Dalakas MC
Rev Neurol (Paris); 2002 Oct; 158(10 Pt 1):948-58. PubMed ID: 12407303
[TBL] [Abstract][Full Text] [Related]
40. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies.
Mirabella M; Alvarez RB; Bilak M; Engel WK; Askanas V
J Neuropathol Exp Neurol; 1996 Jul; 55(7):774-86. PubMed ID: 8965093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
